Eterna Therapeutics Inc On March 19, Received A Notice From Nasdaq Stating That Co Is Not In Compliance With Nasdaq Listing Rule 5550(B)(1)
Portfolio Pulse from Benzinga Newsdesk
Eterna Therapeutics Inc received a notice from Nasdaq on March 19, indicating non-compliance with Nasdaq Listing Rule 5550(B)(1), according to an SEC filing.
March 22, 2024 | 8:37 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Eterna Therapeutics Inc received a notice from Nasdaq for not complying with Listing Rule 5550(B)(1), as per an SEC filing.
Receiving a notice of non-compliance from Nasdaq is a significant regulatory issue that can affect investor confidence and potentially lead to further actions by Nasdaq, including delisting. This news is directly related to Eterna Therapeutics and is critical for investors to monitor, as it could impact the stock's performance in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100